Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: PTC Therapeutics, Inc.

Market Cap 6.2B 5.35B 4.93B 4.62B 8.65B 589B 8.79B 58.24B 22.71B 287B 23.26B 22.76B 993B P/E Ratio 2026 *
84.3x
P/E Ratio 2027 * 29.9x
Enterprise Value 4.41B 3.81B 3.51B 3.29B 6.16B 419B 6.26B 41.48B 16.17B 204B 16.56B 16.21B 707B EV / Sales 2026 *
3.76x
EV / Sales 2027 * 3.32x
Free-Float
92.62%
Yield 2026 *
-
Yield 2027 * -
1 day+0.56%
1 week+5.79%
Current month+1.67%
1 month+0.08%
3 months+18.50%
6 months-0.74%
Current year-1.16%
1 week 69.74
Extreme 69.74
75.93
1 month 67.16
Extreme 67.165
75.93
Current year 61.43
Extreme 61.43
80.18
1 year 43.18
Extreme 43.175
87.5
3 years 17.53
Extreme 17.53
87.5
5 years 17.53
Extreme 17.53
87.5
10 years 4.03
Extreme 4.03
87.5
Manager TitleAgeSince
Chief Executive Officer 54 2023-03-21
Director of Finance/CFO 41 2023-07-12
Chief Tech/Sci/R&D Officer - 2017-09-30
Director TitleAgeSince
Chairman 74 2004-10-31
Director/Board Member 80 1998-03-30
Director/Board Member 65 2005-11-30
Date Insider Type Main position Quantity % Market Cap.
05-14Fiscal year

General Counsel

8,436 0.0102%
05-13Sell

Chief Executive Officer

-12,572 0.0152%
05-07Fiscal year

General Counsel

10,620 0.0128%
Change 5-day change 1-year change 3-year change Capi.($)
+0.59%+5.79%+47.27%+73.19% 6.2B
-2.19%+0.55%+40.10%+155.47% 1,035B
+0.82%+3.42%+53.67%+50.56% 574B
+0.98%-0.22%+17.84%+64.63% 397B
+0.58%+0.77%+21.19%+15.95% 324B
-0.85%-2.86%+22.05%+13.80% 281B
+0.44%+3.48%+24.48%+34.39% 278B
+1.66%+5.61%-44.67%-47.49% 193B
-0.10%+1.26%+19.07%+62.85% 191B
-0.34%-2.77%+12.07%+61.29% 156B
Average +0.18%+2.09%+21.31%+48.46% 343.61B
Weighted average by Cap. -0.32%+2.39%+28.07%+71.91%

Financials

2026 *2027 *
Net sales 1.17B 1.01B 934M 874M 1.64B 112B 1.66B 11.03B 4.3B 54.28B 4.4B 4.31B 188B 1.31B 1.13B 1.04B 978M 1.83B 125B 1.86B 12.33B 4.81B 60.72B 4.93B 4.82B 210B
Net income 65.46M 56.53M 52.1M 48.77M 91.39M 6.22B 92.8M 615M 240M 3.03B 246M 240M 10.49B 178M 154M 142M 133M 248M 16.91B 252M 1.67B 652M 8.23B 668M 653M 28.5B
Net Debt -1.78B -1.54B -1.42B -1.33B -2.49B -170B -2.53B -16.76B -6.54B -82.53B -6.69B -6.55B -286B -1.84B -1.59B -1.46B -1.37B -2.57B -175B -2.61B -17.29B -6.74B -85.14B -6.91B -6.76B -295B
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
991
Date Price Change Volume
26-06-12 75.10 $ +0.52% 697,872
26-06-11 74.71 $ +1.85% 2,245,458
26-06-10 73.35 $ -0.45% 1,211,358
26-06-09 73.68 $ +3.97% 1,873,819
26-06-08 70.87 $ -0.14% 1,293,398
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
74.71USD
Average target price
93.93USD
Spread / Average Target
+25.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTCT Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!